TrialPharmacology research & perspectives2017

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide.

Joseph M Custodio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.